CymaBay Therapeutics, Inc. CBAY Cash Flow

Cymabay therapeutics, inc. (CBAY)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net loss
-92,821	-102,808	-92,844	-85,125	-78,618	-72,548	-58,142	-47,813	-39,211	-27,557	-29,466	-27,111	-25,174	-26,671	-25,698	-25,684	-20,049	-15,529	-22,272	-22,368	-24,183	-31,917	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
587	572	488	358	231	105	48	42	38	35	34	36	33	29	26	22	21	22	22	21	21	18	0	0	0
Non-employee stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34	8	0	0	0
Stock-based compensation expense
9,214	9,558	9,221	8,084	7,559	7,013	6,257	5,349	5,438	4,920	4,614	4,461	3,192	2,473	2,410	2,305	2,341	2,487	2,146	1,807	1,275	1,284	0	0	0
Amortization of premium on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	511	511	503	549	453	0	0	0
Net accretion and amortization of investments in marketable securities
1,898	2,237	2,496	2,492	2,211	1,945	1,510	980	476	199	50	4	-18	-125	-204	-275	-283	-228	-206	-193	-200	-198	0	0	0
Non-cash interest associated with debt discount accretion
-	-	-	-	-	148	246	353	409	437	463	479	483	476	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	3,700	4,487	7,316	8,293	5,773	4,964	3,084	2,379	-75	-179	-1,180	-6,866	-11,121	-6,038	-4,700	-2,123	7,236	0	0	0
Changes in assets and liabilities:
Receivable from collaboration
-	-	-	-	-	-5,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid research and development expenses and other prepaid assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest receivable and other current assets
-104	383	290	320	208	178	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-2	-116	-165	0	0	0	-	-	-	-	-	-	-	-
Contract receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	7	-168	101	0	0	0
Accrued interest receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	-51	109	68	0	0	0
Prepaid expenses
-	-	-	-	-	-	425	1,005	239	-161	294	97	561	761	-417	33	-796	-1,383	89	-479	-513	1,627	0	0	0
Other assets
-	-2,120	-102	-633	142	1,646	0	0	0	-	-	-	-	-	-	-	-	486	-52	-233	-172	-3	0	0	0
Accounts payable
-1,197	530	-135	1,546	372	662	545	235	942	412	149	-171	-681	-109	228	-449	250	-1,077	-340	459	458	1,388	0	0	0
Accrued restructuring charges
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued liabilities
-3,290	-669	3,568	2,401	6,791	6,450	8,118	6,350	1,418	1,387	910	685	805	1,015	-1,056	-264	-258	-46	27	388	669	1,889	0	0	0
Accrued interest payable
-	-	-	-	-	-43	-49	-55	-23	-23	0	0	0	-	-	-	-	-	-	-	-	107	0	0	0
Other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	10	11	13	0	0	0
Net cash used in operating activities
-90,206	-97,900	-89,395	-82,272	-70,889	-54,936	-41,413	-30,802	-23,870	-19,632	-18,962	-19,237	-19,416	-23,353	-23,147	-24,066	-23,305	-23,324	-25,600	-22,832	-22,262	-21,114	0	0	0
Investing activities
Purchases of property and equipment
-	315	758	752	661	529	0	0	0	-	-	-	-	-	-	-	-	-	-	-	71	103	0	0	0
Purchases of marketable securities
265,499	290,893	273,140	311,735	242,336	276,382	258,866	274,488	214,204	98,385	92,543	15,024	31,030	22,906	20,320	47,117	37,171	42,788	0	0	0	-	-	-	-
Proceeds from maturities of marketable securities
286,966	252,881	253,081	264,769	265,517	222,800	183,169	115,266	60,318	30,884	29,735	24,520	35,345	50,076	43,883	45,333	44,620	31,705	29,928	29,296	17,633	10,499	0	0	0
Proceeds from sale of marketable securities
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
21,330	-34,347	-16,837	-43,738	26,500	-54,111	-75,784	-159,295	-153,959	-67,528	-62,808	9,491	4,273	27,128	23,521	-1,821	7,449	-11,083	-14,396	-231	-16,389	-16,938	0	0	0
Financing activities
Proceeds from issuance of common stock, net of issuance costs
-	107,746	107,746	107,746	107,920	135,520	135,369	226,592	226,592	100,436	0	0	0	-	-	-	-	25,375	25,375	27,291	27,291	25,430	0	0	0
Proceeds from issuance of common stock pursuant to equity award plans
-	386	128	154	392	3,571	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock upon exercise of warrants
-	-	-	-	-	2,600	0	0	0	-	-	-	-	-	-	-	-	426	0	0	0	-	-	-	-
Repayment of facility loan principal
-	-	-	-	-	6,527	7,337	8,130	3,207	3,137	0	0	0	-	-	-	-	4,756	0	0	0	-	-	-	-
Cash provided by financing activities
-	108,132	107,874	109,413	104,382	134,988	135,983	225,314	229,737	99,719	0	0	0	-	-	-	-	30,527	30,331	26,763	27,150	25,237	0	0	0
Net increase in cash and cash equivalents
-68,780	-24,126	1,667	-16,645	59,993	25,941	18,786	35,217	51,908	12,559	16,188	-2,902	-7,524	2,789	130	709	10,356	-3,880	-9,665	3,700	-11,501	-12,815	0	0	0
Supplemental disclosure
Cash paid for amounts included in the measurement of lease liabilities
632	628	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	231	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	435	0	0	0
Supplemental non-cash investing and financing activities
Accrued financing costs
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fixed assets in accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Issuance of common stock warrants to lenders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	443	0	0	0
Issuance of common stock upon warrant exercises
-	-	-	-	-	9,379	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	549	0	0	0
Noncash issuance costs incurred in common stock financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	453	0	0	0